Podcasts about therap

El Dr. Francisco Zambrana Tévar, oncólogo médico del Hospital Universitario Infanta Sofía, San Sebastián de los Reyes en Madrid, España presentó un análisis de los estudios más relevantes del año 2024 en cáncer de próstata.STAMPEDE: estudio fase II/III, controlado aleatorizado de múltiples brazos y múltiples etapas. Su objetivo es evaluar múltiples estrategias terapéuticas en el tratamiento del cáncer de próstata metastásico localmente avanzado y de alto riesgo sin tratamiento hormonal.DIPPER: estudio fase II, abierto, multicéntrico y aleatorizado  de radioterapia de rescate temprana versus vigilancia para la recurrencia bioquímica después de una prostatectomía radical que incorpora estratificación del riesgo basada en la clínica y en imágenes.EMBARK: estudio fase III, aleatorizado que evalúa la eficacia y seguridad de enzalutamida más leuprolida, enzalutamida en monoterapia y placebo más leuprolida en pacientes con cáncer de próstata no metastásico de alto riesgo que progresaron después de una terapia definitiva.HORRAD: estudio fase III, aleatorizado, que evaluó el impacto de la radioterapia dirigida al tumor primario en pacientes con cáncer de próstata metastásico al momento del diagnóstico.PEACE-1: estudio fase III, prospectivo y aleatorizado que evalúa la terapia de deprivación androgénica sola o en combinación con docetaxel, radioterapia local y/o acetato de abiraterona con prednisona en pacientes con cáncer de próstata metastásico aún sensible a la castración.CHAARTED: estudio aleatorizado de terapia de ablación androgénica con o sin quimioterapia en el tratamiento de pacientes con cáncer de próstata metastásico.CARD: esudio fase III, aleatorizado que evaluó la eficacia de cabazitaxel en comparación con la reintroducción de abiraterona o enzalutamida en pacientes con cáncer de próstata metastásico resistente a la castración que ya habían recibido previamente docetaxel y una línea de terapia hormonal de nueva generación (abiraterona o enzalutamida).TheraP: estudio fase II, aleatorizado y de etiqueta abierta que comparó Lu177-PSMA-617 vs. cabazitaxel en pacientes con cáncer de próstata metastásico resistente a la castración previamente tratados con docetaxel.IMPACT: ensayo clínico fase III que evaluó la eficacia de sipuleucel-T en pacientes con cáncer de próstata metastásico resistente a la castración asintomático o mínimamente sintomático.Entre otros...  Fecha de grabación: noviembre de 2024.                     Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

In deze podcast spreekt prof. dr. Lioe-Fee de Geus-Oei, nucleair geneeskundige aan het Leids Universitair Medisch Centrum te Leiden, met dr. Daniela Oprea-Lager, nucleair geneeskundige aan het Radboudumc te Nijmgen, over de laatste ontwikkelingen op het gebied van diagnostiek en therapie met prostaatspecifiek membraanantigeen, oftewel PSMA. Wat betreft diagnostiek worden de verschillende type tracers besproken, hun biodistributie en pittfals en de voordelen van PSMA-PET/CT ten opzichte van conventionele imaging conform de bevindingen van de proPSMA-trial. Wat betreft therapie komt de VISION- en de TheraP-trial aan bod en worden de belangrijkste resultaten voor deze twee patiëntenpopulaties besproken voor wat betreft progressievrije en totale overleving, objectieve respons, skeletgerelateerde events en bijwerkingen. Ook wordt besproken wanneer patiënten in aanmerking komen voor deze therapie en welke dosering er met welk interval gegeven wordt.Referenties Hofman MS, et al. Lancet 2020;395:1208–16. Hofman MS, et al. Lancet 2021;397:797–804. Sartor O, et al. N Engl J Med 2021;385:1091-103.

Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.

Dear Adult Child Listeners.I recently sat down with Dr Joy Bracey & had a heart opening & mind blowing conversation about adult childrens trauma response to eating our feelings which soothed our developing nervous system, helped us feel safe & calmed us down when no adult caregiver was available or able to and how we can love ourselves free of the past with self-care tools to stay present with mindfulness. awareness & self-acceptance.Dr. Joy Bracey, a licensed therapist, self-love & mindfulness teacher, public speaker, single mom of four, and successful non-profit CEO, has lived with the disease of obesity her entire adult life. After many cycles of weight loss and weight gain and struggles with diet culture, she embraced her curves, claimed body positivity, and let go of her fantasies of fitting back into her college jeans. Then, at age 47, she began a self-love journey that put her on track to get honest with herself about the costs of living in a body that was 337 pounds and climbing. Realizing that the life of freedom she wanted for herself was not possible at her size, she started considering medical solutions and documented her journey of self-discovery in a podcast called, "The Easy Weigh Out". In the 6-episode docuseries, she talks to friends and family, a therapist, and an obesity medicine specialist. They get very personal about the emotional reasons for gaining and maintaining drastic amounts of weight, food addiction, "fat-vantanges", what it's like to live in a 300+ pound body, the impact of fat-shaming and fatphobia on women and girls, why it's not about "eat less and move more" or willpower, and the medical and genetic causes and consequences of obesity. She and her adult children discuss what it was like for them growing up in a "fat" family with a mom who was always trying to lose weight, how they wish she'd have handled their "chubbiness", and their fear for her life. Dr. Joy goes to therapy with a fellow therapist who had weight loss surgery and gets deep with her lifelong best friend about the feeling of safety that comes with living in a bigger body, her fear of being thin, sex and dating while fat, and so much more.Her podcast is not just any conventional weight loss podcast, but a radical, touching, and honest look into the underlying emotions that go along with any unhealthy coping mechanisms- from the perspective of a mental health professional who is willing to be vulnerable in sharing her story while exploring the complex societal relationship between the perks of fatness, cultural obsession with thinness, faulty coping mechanisms, and mental, emotional & physical health. She crosses the line between body positivity and health consciousness in way that few people can, but is relatable to everyone. Visit her website to learn more at https//drjoybracey.com Learn more & visit my inner child library at https://vandanalighthealing.com

Welcome to Therap-ised! In this episode, join us for an insightful conversation with Simran Kaur, the acclaimed author of the best-selling book "Women Who Invest." Our focus in this episode is "Investing Beyond Boundaries: A Journey of Women in Finance with Simran Kaur."  Simran, a trailblazer in the finance world, takes us on a compelling journey, exploring the uncharted territory of women in the realm of investment and finance. Through her extensive knowledge and experiences, she delves into the challenges, triumphs, and the transformative power of women's involvement in finance.  Simran sheds light on breaking barriers, embracing diversity, and the essential role of women in shaping the financial landscape. We also focus on the relationship (including guilt) that women can hold with money which can often subconsciously limit or stop growth. Join us as we navigate a deep dive and discover the path to investing beyond conventional boundaries.  ————————————  To connect with Simran:  Instagram: @girlsthatinvest @ms.simran.kaur  Website: https://girlsthatinvest.com  TikTok: https://www.tiktok.com/@girlsthatinvest Facebook: https://www.facebook.com/groups/620511298746021/

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss the CLEAR study in renal cell carcinoma, a new exploratory analysis combining the TheraP and VISION trials in metastatic urothelial cancer, and compelling advances in prostate cancer and across GU oncology in advance of the 2023 ASCO Annual Meeting.  TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host for the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical director of the Genitourinary Cancers Program at the Inova Schar Cancer Institute in Virginia.   Today, we'll be discussing some key abstracts in GU oncology that will be featured at the 2023 ASCO Annual Meeting.  Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcript at asco.orgDNpod.   Jeanny, it's great to have you on the podcast today. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal, for having me. Dr. Neeraj Agarwal: Jeanny, let's begin with Abstract 4502 regarding long-term updated results on the CLEAR study. The abstract reports the final, prespecified overall survival analysis of the CLEAR trial, a four-year follow-up of lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yes, I would be happy to. So, just as a reminder, the combination of lenvatinib and pembrolizumab was initially approved by the FDA in August 2021 for first-line treatment of adult patients with advanced renal cell carcinoma. So, this was based on significant benefits that were seen in progression-free survival, which was a primary endpoint, but also showed improvement in the overall response rates compared with sunitinib in first-line advanced renal cell carcinoma.   So this abstract reports on longer-term follow-up now at a median of 49.8 months, and PFS favored the combination lenvatinib and pembrolizumab compared to sunitinib across all MSKCC risk groups, and PFS benefit versus lenvatinib and pembro compared to sunitinib was maintained with a hazard ratio of 0.47. And even overall survival was also maintained with the combination with a hazard ratio of 0.79, and the overall survival favored the combination across all risk groups. If we look at the CR rate, it was 18.3% for the combination compared to 4.8% with sunitinib, unless patients in the combination arm received subsequent anticancer therapies, and that's intuitive. And the PFS2 was also longer with the combination at 43 months compared to 26 months. Now, it is important to note that grade III or more treatment-related adverse events did occur in about 74% of the patients in the combination of lenvatinib and pembro, compared to 60.3% in patients with sunitinib. Dr. Neeraj Agarwal: Jeanny, this is good news. So the main message from the abstract is that sustained results from this combination of lenvatinib plus pembrolizumab are being seen even after a longer follow-up of more than four years.  Dr. Jeanny Aragon-Ching: Yes, I agree. So now, moving on, Neeraj, to a different setting in the RCC space, let's look at Abstract 4519, which is titled “Efficacy of First-line Immunotherapy-based Regimens in Patients with Sarcomatoid and/or Rhabdoid Metastatic Non-Clear Cell RCC: Results from the IMDC,” which will be discussed by Dr. Chris Labaki. So, Neeraj, based on this abstract, can you tell us a little bit more about the impact of these adverse pathologic risk features in non-clear cell RCC?  Dr. Neeraj Agarwal: Of course. So, using real-world patient data, the IMDC investigators compared the outcomes of patients with metastatic non-clear cell RCC who were treated with immunotherapy-based combination regimens versus those who were treated with VEGF-TKIs alone. They also assessed the impact of sarcomatoid and rhabdoid features on response to IO-based combinations versus VEGF-TKIs. Of 103 patients with metastatic non-clear cell RCC who had rhabdoid or sarcomatoid features, 32% of patients were treated with immunotherapy-based combinations.   After adjusting for confounding factors, the authors show that those treated with a combination of two immune checkpoint inhibitors or an immune checkpoint inhibitor with a VEGF-TKI combination had significantly improved overall survival, which was not reached in the immunotherapy combination group versus seven months within the VEGF-TKI group. Time to treatment failure and objective responses were also prolonged, significantly higher, and better in the immunotherapy groups compared with patients who were treated with VEGF-TKIs alone. Interestingly, if you look at those 430 patients with metastatic non-clear cell RCC who did not have sarcomatoid or rhabdoid features, they didn't seem to benefit with immunotherapy-based combinations.  Dr. Jeanny Aragon-Ching: This is an exciting update, Neeraj. What are the key takeaways from this abstract? Dr. Neeraj Agarwal: So the main takeaway is if you see a patient with advanced non-clear cell RCC who has sarcomatoid and rhabdoid features, there appears to be a rather substantial and selective benefit with IO-based combinations. And in this context, I would like to highlight the ongoing SWOG 2200 trial also known as PAPMET2 trial, which is comparing the combination of cabozantinib plus atezolizumab. So immuno-therapy-based combinations versus cabozantinib alone in advanced papillary renal cell carcinoma setting. So this trial is being led by Dr. Benjamin Maughan and Dr. Monty Pal. And I like to encourage our listeners to consider referring their patients for involvement in this federally funded trial so that we can validate the data from this retrospective study in a prospective way. So, Jeanny, let's now move on to another important disease type which is urothelial carcinoma. There is a very recent accelerated FDA approval of the drug combination of enfortumab vedotin and pembrolizumab for cisplatin-ineligible metastatic urothelial carcinoma patients. This is Abstract 4505, which is being presented by Dr. Shilpa Gupta and colleagues. Can you please tell us more about this update? Dr. Jeanny Aragon-Ching: Yeah, absolutely. So, as you mentioned, Neeraj, the FDA just granted accelerated approval in April 2023 for this combination of enfortumab vedotin or EV, which is and ADC, antibody drug conjugate against nectin-4 and the PD-1 inhibitor pembroluzimab. So it's a combination for patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible. So this is nearly a four-year follow-up.   So as a reminder, this was a phase 1b/2 trial that included 45 patients and it had a primary endpoint of safety and tolerability although the key secondary endpoints included confirmed overall responses, duration of response, progression-free survival, and the resist criteria was investigated via investigator and BICRs which is in a blinded independent central review. Even overall survival was a key secondary endpoint.  So, the bottom line was the confirmed overall response by BICR was 73.3%, the disease control rate was about 84%, and the CR rate was 15.6% with a PFS of close to 13 months, and a 12-month overall survival rate of 83%. However, it is important to cite that there were treatment-related adverse events including skin reactions in 66%, neuropathy occurred in 62%, and ocular disorders in 40%. And there was a little bit of pneumonitis in close to 9%, colitis, and hypothyroidism, so there are side effects to watch out for.  Dr. Neeraj Agarwal: So, Jeanny this is great. What is the key takeaway from this trial?  Dr. Jeanny Aragon-Ching: So I think the most important thing is we now have a new combination of EV and pembro which shows very promising responses and survival in part which led to the FDA accelerated approval in the cisplatin-ineligible population of patients. However, we must note that the phase 3 trial of EV302 will ultimately establish which approach is really beneficial for all of our cisplatin-ineligible patients, either a carboplatin-based chemotherapy regimen or a non-platinum-based regimen such as EV and pembro. Dr. Neeraj Agarwal: Thanks Jeanny, would you like to discuss any other study in the bladder cancer space? Dr. Jeanny Aragon-Ching: Absolutely. I think Abstract 4508 from Dr. Seth Lerner and colleagues will be very relevant to our colleagues. This abstract is SWOG S1011, which is a phase 3 surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at the time of radical cystectomy for muscle-invasive bladder cancer.  Dr. Neeraj Agarwal: Yes. So this trial, as you said, is an important trial which randomized in a one-on-one fashion 618 patients with muscle-invasive bladder cancer undergoing radical cystectomy, and these patients were randomized to either standard lymph node dissection or an extended lymph node dissection. And standard lymph node dissection included, as we know, external and internal iliac and operative lymph node. The extended lymph node dissection included lymph nodes up to aortic bifurcation which included common iliac, presciatic, and presacral lymph nodes. At a median follow-up of approximately 6 years, there was no disease-free survival or overall survival benefit in patients undergoing an extended lymph node dissection compared to standard lymph node dissection. And extended lymph node dissection was also associated with greater morbidity and preoperative mortality. Dr. Jeanny Aragon-Ching: Very interesting data, Neeraj. So these results, I think, will be very useful for a lot of our surgical colleagues in both academia and the community who may still be inclined to perform extended lymphadenectomy during cystectomy. This study shows that it's actually not necessary. Dr. Neeraj Agarwal: Absolutely. So now let's move on to another disease type, which is very important - prostate cancer. There are several practice-informing abstracts that are worthwhile discussing. The first of these involves Abstract 5002, which looks at the impact of the PSA nadir as a prognostic factor after radiation therapy for localized prostate cancer, which will be presented by Dr. Praful Ravi and  colleagues. Jeannie, can you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Yeah, definitely. So this abstract, as you mentioned, Neeraj, is a prognostic impact of PSA nadir of more than or equal to 0.1 nanogram per ml within six months after completion of radiotherapy for localized prostate cancer - an individual patient data analysis of randomized trials from the ICECaP Collaborative. Basically, it refers to an attempt to evaluate early surrogate measures to predict for long term outcomes such as prostate cancer-specific survival, metastases-free survival, and overall survival. So they looked at a big registry from the ICECaP collaboration that included 10,415 patients across 16 randomized controlled trials. And those men underwent treatment for intermediate risk and high risk prostate cancer treated with either radiation therapy alone in about a quarter of patients, or they got RT with short-term ADT in about 58% of patients, and 17% of them got RT with long-term ADT.  So, after a median follow-up of ten years, what they found was, if you had a PSA nadir that is over or equal to 0.1 nanogram per ml within six months after completion of radiation therapy, it was associated with worse prostate cancer-specific survival, metastases-free survival, and overall survival. For instance, the five-year metastases-free survival for those who achieved a PSA nadir of less than 0.1 was 91% compared to those who did not, which was 79%. Therefore, they concluded that if you achieve a bad PSA of 0.1 or above within six months after you completed radiation, you had worse outcomes.  Dr. Neeraj Agarwal: Jeanny, what is the key takeaway message from this study? Dr. Jeanny Aragon-Ching: The key takeaway from this ICECaP analysis is that this information would be very important to augment a signal-seeking endpoint, especially for clinical trial development, so that we can develop further strategies to de-escalate for those who don't need systemic intensification or therapy intensification versus escalation for those who really do. Dr. Neeraj Agarwal: So, my radiation oncology colleagues need to watch out for those patients who do not achieve a PSA of less than 0.1 nanogram per ml within the first six months of finishing radiation therapy. Very interesting data.  Dr. Jeanny Aragon-Ching: Yes, absolutely. So. Neeraj another important abstract for our fellow clinicians, switching gears a little bit now, is Abstract 5011, which is titled “Do Bone Scans Overstage Disease Compared to PSMA PET?” This was an international, multicenter retrospective study with blinded, independent readers. Can you tell us more about this abstract? Dr. Neeraj Agarwal: Yes, a relatively small retrospective study, but still pertinent to our practice. So I'll summarize it. This study by Dr. Wolfgang Fendler and colleagues evaluated the ability of bone scans to detect osseous metastasis using PSMA PET scan as a reference standard. So in this multicenter retrospective study, 167 patients were included, of which 77 patients were at the initial staging of prostate cancer, 60 had biochemical recurrence after definitive therapy, and 30 patients had CRPC or castor-resistant disease.  These patients had been imaged with a bone scan and a PSMA PET scan within 100 days. And in all patients, the positive predictive value, negative predictive value and specificity for bone scan were evaluated at different time points. They had bone scan and PSMA PET scan and both were compared. And what they found was interesting. All these three values - positive predictive value, negative predictive value, and specificity for bone scan were 0.73, 0.82 and 0.82 in all patients, and in initial staging, it was even lower at 0.43 and 0.94 and 0.80.  So, without getting into too much detail regarding these numbers, I want to highlight the most important part of the study, that at the initial staging, 57% patients who had a positive bone scan had false positive bone scans. The interreader agreement for bone disease was actually moderate for bone scans and quite substantial for the PSMA PET scan.  Dr. Jeanny Aragon-Ching: So, Neeraj, what do you think is the key takeaway message here for our audience?   Dr. Neeraj Agarwal: The key takeaway message is that positive predictive value of bone scan was low in prostate cancer patients at initial staging, with the majority of positive bone scans being false positive. This suggests that a large proportion of patients which we consider to have low-volume metastatic disease by bone scan actually have localized disease. So in the newly diagnosed patients with prostate cancer, patients should ideally have a PSMA PET scan to rule out metastatic disease.   So, let's move on to another abstract I would like to discuss, which has important implications in treatment, especially now that lutetium 177 is approved, but frankly not available widely. Dr. Jeanny Aragon-Ching: Yeah, that's actually very timely. So the abstract you're referring to is 5045, which is being presented by Dr. Yu Yang Sun and colleagues entitled “Effects of Lutetium PSMA 617 on Overall Survival in TheraP Versus VISION Randomized Trials: An Exploratory Analysis.” So, Neeraj, can you tell us more about the relevance of this exploratory analysis? Dr. Neeraj Agarwal: Definitely. In this abstract, Dr. Yang Sun and colleagues assess the effect of lutetium PSMA on overall survival in two different trials, TheraP and VISION trials. So, just for our listeners' recollection, the phase 2 TheraP trial compared lutetium PSMA and cabazitaxel in patients with mCRPC who had progression on docetaxel and had significant PSMA avidity on gallium PSMA pet scan, which was defined as a minimum uptake of SUV max of 20 at least one site of disease and SUV max of more than 10 at all sites of measurable disease.  In this trial, 20 of 101 patients in the cabazitaxel arm crossed over to lutetium PSMA, and 32 of 99 patients in the lutetium PSMA arm crossed over to cabazitaxel. In the VISION trial, patients with mCRPC who previously progressed on at least one ARPI and one taxane-based therapy and had a positive gallium PSMA scan, and here, positivity was not stringently pre-specified as it was done in the context of TheraP trial. So, positive gallium pet scans were randomly assigned in two to one fashion to receive either lutetium PSMA plus best supportive care or standard of care versus standard of care.  And I'd like to highlight that the standard of care comprised ARPIs and bone protecting agents and these patients were not allowed to have cytotoxic chemotherapy such as cabazitaxel in the standard of care arm. Now, overall survival was similar in the lutetium PSMA group regardless of whether they got lutetium PSMA in the VISION trial or TheraP trial. There was no difference in overall survival with lutetium in the lutetium arms of VISION and TheraP trial with a hazard ratio of 0.92. And there was no difference in the overall survival between the lutetium PSMA and the cabazitaxel group in the TheraP trial if you use counterfactual analysis, assuming crossover had not occurred. So, quite interesting in my view. Dr. Jeanny Aragon-Ching: Yeah, thanks Neeraj for that wonderful synopsis and discussion. So, what is the key take home message then? Dr. Neeraj Agarwal: The main message in this new exploratory analysis, which combined both the TheraP and VISION trials, is that lutetium PSMA and cabazitaxel seem to be associated with similar overall survival benefit in these highly selected patients with PSMA positivity. Additionally, the difference in the observed effect of lutetium PSMA and overall survival in the TheraP and VISION trials may be actually better explained by the use of different treatments in the respective control arms of these trials. And these results, in my view, are quite pertinent for those patients and providers who do not have access to lutetium-177 therapy.  Let's go to another abstract that is currently relevant to our practice, given many patients with advanced prostate cancer who have concurrent diabetes; I'm talking about Abstract 5066. Jeanny, can you please tell us more about this abstract?  Dr. Jeanny Aragon-Ching: Certainly, Neeraj. So this abstract will be presented by Dr. Amy Shaver and colleagues. So it's also very relevant, since many men who are diagnosed with prostate cancer frequently also have a concomitant diagnosis of type 2 diabetes mellitus. So, this was a SEER-Medicare population database analysis that looked at men who were treated with either abiraterone or enzalutamide and also had concomitant diagnosis of type 2 diabetes mellitus (DM). And they were identified using ICD-9 and ICD-10 codes and they were all tied in to acute care utilization. So they looked at CMS research data codes and ER hospitalization visits six months after treatment initiation was recorded. So all in all, they took a sample of 11,163 men, of whom close to 62% were treated with abiraterone and about 38% were treated with enzalutamide.  So, of these, about 27% of them had type 2 DM, of whom 59% received abiraterone and about 41% had enzalutamide. So, the bottom line is, compared to those without diabetes mellitus, those who had type 2 diabetes had worse acute care utilization, which was 43% higher than those who got abiraterone compared to enzalutamide, and also had higher overall mortality. Therefore, the bottom line is, having type 2 diabetes mellitus, unfortunately, portends worse outcomes in men with prostate cancer, so careful attention needs to be paid to those who are starting out already with such comorbidities. So Neeraj, any final thoughts you have regarding this abstract and overall before we wrap up on the podcast today?  Dr. Neeraj Agarwal: Absolutely. So it looks like, based on this very important pertinent Abstract 5066, which talks about the impact of diabetes on our patients, I think we need to be very watchful regarding the impact of diabetes on our patients who are being treated with abiraterone or enzalutamide, especially drugs which are known to make the metabolic syndrome and diabetes worse. I think close monitoring and close attention to control of diabetes is very important. So with that, I would urge the listeners to come and join us at the Annual Meeting, not only to celebrate these successes but also to help disseminate this cutting-edge data to practitioners and maximize the benefit to our patients across the globe.   And thank you to our listeners for joining us today. You will find links to the abstracts we discussed today on the transcript of this episode. Finally, if you value the insights that you hear on our ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant,  Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics.

Lutetium PSMA (Lutetium-177), theranostic medicine and future advances in prostate cancer are coming to an oncology centre near you faster than you can say "novel drug development" and "progression-free survival". This week Michael and Josh conclude their epic prostate cancer trilogy by exploring theranostic medicine and radioactive drug development while looking at the past of the cytotoxic world and the role of cabazitaxel. To ensure we keep your attention, six trials are discussed today, and a shout out to TheraP, the Australian phase 2 trial from the land down under.Links to studies discussed in this episode (subscription may be required):Tropic trial: https://www.thelancet.com/article/S0140-6736(10)61389-X/fulltextCARD trial: https://www.nejm.org/doi/full/10.1056/nejmoa1911206Corn et al: https://pubmed.ncbi.nlm.nih.gov/31515154/TheraP: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00237-3/fulltextVision: https://www.nejm.org/doi/full/10.1056/nejmoa2107322For more episodes, resources and blog posts, visit www.inquisitiveonc.comFind us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of:- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Trigger Warning: This episode discusses suicide, ambiguous loss, dementia, Parkinson's disease, and terminal illness.Robin Williams is known as one the many actors that we lost too soon, but do we have a clear understanding as to why? Listen in as Kayla explains a terrible disease that served as a silent killer and whose origins are still unknown.

On the latest episode of The Cannabis Conversation, we're joined by Carola Pérez, president of the Observatorio Español de Cannabis Medicinal, and founder of the patient association - dosemociones.We explore what's happening with medical cannabis in Spain as well as recreational use, and how the social clubs work in Spain.The Cannabis Conversation is sponsored by Lumino - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.Get in touch at www.luminorecruit.com/About Carola PérezCarola is the president of the Observatorio Español de Cannabis Medicinal and founder of the patient association dosemociones. She has been working tirelessly since 2014 for patients' rights, helping and advising on the properties of medical cannabis in Spain. Carola is also chair of the IACM Patient Council, an international coalition of patients' organizations that have gathered together to help give a voice to patients the world over and to work together in order to protect their rights and interests in the ever-developing world of medicinal cannabis.ResourcesConnect with Carola on LinkedIn: https://www.linkedin.com/in/carola-p%C3%A9rez-73890ab5dosemociones's Website: http://www.dosemociones.com/Follow Carola on Instagram: https://www.instagram.com/carolaperez/Follow Carola on Twitter: https://twitter.com/carolaperez

The first one, -itis, meaning “an inflammation of, an inflammatory disease of.” In a medical context, that suffix has adopted the specialized sense of “inflammation” and occurs broadly ─ arthritis, bursitis, appendicitis, etc. The second suffix, -oma which has a basic sense of cancer or tumor. Here's something you need to become used to about all the medical terms we're looking at. The third suffix, -osis (“the diseased condition of”). It's what the suffix -sis (“the act of”) becomes when it checks into a hospital. And note please that, when an -osis word is turned into an adjective, it becomes -otic, like psychosis and psychotic. ARTHR- (“joint, speech sound or articulation”) and going through SCLER- (“hard”). Athrosclerosis [ är′thrō-sklə-rō′sĭs ] – Stiffness or hardening of the joints. ____________________________________________________________________________ Next, let's dive into -ectomy (“the surgical removal of”), which should look very familiar to you. It's a combination of the prefix ec- (“out”) and the base TOM- (“cut”). Like anatomy (“to cut up”) or eccentric (“out of the center”). It means the doctor's cutting something out. The next suffix -tomy (“a surgical operation on, a surgical cutting of”) is just -ectomy without the -ec-, so -tomy's happen when the doctor cuts into something but doesn't take it out. And it doesn't have to be a doctor necessarily. You should also know that there is a medical suffix -tome meaning “a surgical instrument for cutting,” as in a microtome (an instrument for making small cuts) or an osteotome used for cutting into bone. The final suffix to discuss is -rrhea (“an abnormal discharge”). This is where we get diarrhea (“an abnormal discharge through” the body, is this case.” amenorrhea (“without the month's abnormal discharge) “A-” = without “Mens” = month “-rrhea” = “abnormal discharge” Now, let's shift gears again and look at some more medical suffixes, beginning with -path (“one who suffers from a disease of, one who treats a disease”). This suffix -path is actually a back formation of the next suffix -pathy (“disease of, treatment of disease of or by”). “-iasis,” another “diseased condition” suffix, is an extension of the suffix you've probably seen already, “-sis”. Note: that it can sometimes mean just “the process of,” as in odontiasis, “the process of creating teeth (ODONT-).” That is, this suffix doesn't always take on degeneration, another term you need to remember. Next is the suffix -therapy, meaning “treatment of or by.” As you might guess, there's a base THERAP- which we did not study, meaning “treat, attend to.” In ancient Greek a therapon is an attendant. Next suffix that's medical (-emia, “condition of/presence in the blood”) has many pathologies that can arise and flourish fromm this suffix… One of my favorites because it was one of my first suffixes to learn and fully understand. --- Support this podcast: https://anchor.fm/liam-connerly/support

Let's discuss the effects of modern feminism on dating and men's mental health.

akaRadioRed welcomes three caring Creatives. Arlene Duane Hemingway, a former music teacher and professional organist, writes 100-word “drabble” fiction. Nicole Bueno, LCSW, is a Behavioral Health expert who has helped NCAA athletes improve their mental skills training. Larry Grogan is the author of A Tail of Love, Life Lessons from Scrappy, a Pet Therapy Dog. Join akaRadioRed for Read My Lips: Creativity That Cares.

akaRadioRed welcomes three caring Creatives. Arlene Duane Hemingway, a former music teacher and professional organist, writes 100-word “drabble” fiction. Nicole Bueno, LCSW, is a Behavioral Health expert who has helped NCAA athletes improve their mental skills training. Larry Grogan is the author of A Tail of Love, Life Lessons from Scrappy, a Pet Therapy Dog. Join akaRadioRed for Read My Lips: Creativity That Cares.

Featuring an interview with Dr Sandy Srinivas, including the following topics: Rationale for and efficacy data from the Phase II SALV-ENZA trial of salvage radiation therapy with enzalutamide or placebo for high-risk recurrent hormone-sensitive prostate cancer (0:00) Results from clinical trials evaluating abiraterone, docetaxel or apalutamide for patients with hormone-sensitive prostate cancer (3:29) TheraP trial: Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic hormone-resistant prostate cancer (8:31) Clinical data with abiraterone acetate in combination with PARP inhibition for patients with metastatic hormone-resistant prostate cancer: Results from the PROpel and MAGNITUDE trials (13:54) Current role of neoadjuvant chemotherapy with immunotherapy for patients with metastatic urothelial bladder cancer (UBC); updated long-term outcomes with enfortumab vedotin from the EV-301 trial (20:23) Clinical pearls for preventing and managing adverse events with erdafitinib, sacituzumab govitecan or enfortumab vedotin in patients with UBC (25:23) HER2 expression in UBC and emerging data with the novel HER2-targeted antibody-drug conjugate RC48 alone and in combination with toripalimab; tolerability of antibody-drug conjugates (30:53) Follow-up efficacy and safety data from the KEYNOTE-564 trial; practical implications of the safety data with adjuvant pembrolizumab for renal cell carcinoma (RCC) (36:16) Emerging data with the novel agent belzutifan for advanced clear cell RCC (40:11) Current practice and potential advances in the first-line treatment of metastatic RCC (44:25) CME information and select publications

GU Cast returns to one of our favourite topics - PSMA imaging and theranostics! We chat with Nuclear Medicine Physician Professor Michael Hofman, and GU Medical Oncologist, Associate Professor Arun Azad, about some PSMA highlights at the recent ASCO Annual Meeting. Michael presented the eagerly anticipated overall survival data from the TheraP trial in the oral abstract session, and discusses the findings with Arun, Renu and Declan. They also discuss another important paper in the oral abstract session - an analysis of the quantitative parameters of PSMA PET/CT scans in the VISION study. Also available of our Youtube channel here

Koos van der Hoeven bespreekt met Debbie Robbrecht ontwikkelingen bij blaas- en prostaatcarcinoom. Aan bod komen onder andere de rol van (neo-adjuvante) immunotherapie bij niet-spierinvasief blaascarcinoom, de rol van ctDNA bij spierinvasief blaascarcinoom, cabozanitinib bij gemetastaseerd blaascarcinoom en de TheraP-studie en ENZAMET-studie bij het prostaatcarcinoom.

Therap is a proud sponsor of the 2022 National APSE Conference. Come meet them in June or find Therap online at www.therapservices.net Listen to this podcast from National APSE's Erica Belois-Pacer with Kevin Dierks and Marybeth Julian from Therap. Together, they talk about data, how to use the information to improve services, and Therap's tools… The post APSE Conversations: Therap appeared first on Association of People Supporting Employment First.

Featuring perspectives from Prof Karim Fizazi, including the following topics: Introduction (0:00) Journal Club with Prof Karim Fizazi, MD, PhD (3:40) Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer — Nataliya Mar, MD (16:39) Comments on the PEACE-1 trial by A Oliver Sartor, MD (21:58) Case: Two patients with prostate cancer who received a PARP inhibitor — Helen H Moon, MD (32:18) Case: A man in his mid-60s with metastatic castration-resistant prostate cancer (mCRPC) and a somatic BRCA2 mutation — Rohit Gosain, MD (37:59) Second Opinion by Simon Chowdhury, MD, PhD: A man in his late 60s with mCRPC and a germline BRCA2 mutation (Zanetta S Lamar, MD) (41:40) Comments on the TheraP trial by Dr Sartor (55:29) Immune Checkpoint Inhibitors in mCRPC (58:48) CME information and select publications

In the second conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss the breadth of NASH Drug/Disease Management on the weekend agenda.Louise starts this conversation by pointing out Saturday sessions she believes will be important to understanding Fatty Liver care delivery, including sessions addressing women's health, health service and public health. From there, Ken leads into a discussion of Saturday's post-graduate course and Manal Abdelmalek opens a discussion on Sunday's Presidential Plenary session. She and Jörn note the importance of the presentation that explores longitudinal association between MRE and various outcomes, focusing specifically on the importance of deriving cardiovascular outcomes. Jörn and Roger comment on specific issues around the design of the aldafermin ALPINE 2/3 trial and the implications of clinical vs. commercial failure. As the conversation ends, Manal and Ken identify other science-driven sessions.

Welcome to the Parenting Revolution!Consent...How do we teach it?  And did we ever really learn it ourselves?Check out this week's episode and hear more about why consent is so important. If you are a new listener, we would love to hear from you.  Please consider sending us an email with your suggestions and comments to revolutionparenting@gmail.com. WE HAVE TRANSCRIPTS!!  You can also add your email to our list and have episodes sent right to your inbox! Things we talked about: Nobody was taught consent [1:03]You want your kids to have a voice [7:03]Website for teaching consent (link below) [8:06]Exley's experience at the park [10:03]Having conversations [13:24]Abby hates tickling [17:36]Sharing is caring [25:38]Listening to your kids [27:58]Getting over how we were brought up [32:31]  Website about consent and boundarieshttps://www.safesecurekids.org  Check out Dianne's blog here~https://diannecassidyconsulting.com/milklytheblog/  Here is how you can connect with Dianne and Abby~Abby Theuring  https://www.thebadassbreastfeeder.comDianne Cassidy http://www.diannecassidyconsulting.com

Professor Michael Hofman has contributed to some of the most important progress for imaging and treatment of prostate cancer. And his collaborative approach has brought together multi-disciplinary expertise from more than 10 centers around Australia. – If you have the energy to put together a clinical trial protocol I bet colleagues around your country will be happy to adopt it. It is a win-win for everyone. Please join us in this episode of Theragnostic Talks.   Guest: Prof. Michael Hofman By: Annette Andrén and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se

Welcome back my friends, this week I am humbled and honored to have Mr Love Drive himself, Shaun Galanos. Shaun is a professional speaker, love, communication, and intimacy coach who helps people have better, more loving relationships. His following has been growing at an incredible rate via Instagram over the past few months and that is indicative of the thoughtful, real, and impactful content he produces.Shaun's authenticity is palpable. He offers a handful of online courses through his website https://www.shaungalanos.com/ such as Healthy Communication, Getting Your Needs Met, The Confidence Course, Emotional Availability, and Flirting with Confidence. Much of Shaun's content is focused around answer questions submitted by all his followers and his straight up, to the point narrative, is merely one of the reasons so many people have flocked to listen to his advice.Find Shaun giving you the large dose of hard nosed love and life advice you need via Instagramhttps://www.instagram.com/thelovedrive/

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer. This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

UFO Think Tank Yvonne Smith, Abduction Therap

On this episode of the show, I'm interviewing Dr. Kristan Wilson, a holistic physician who takes a personalized, whole-body approach to conservative healthcare.  Dr. Wilson specializes in functional medicine and is a classically trained, board-certified chiropractic physician and chiropractic acupuncturist. Dr. Kristan Wilson takes great pride in treating everyone as an individual and taking the time necessary to treat the whole person. Her appointments are longer than most other practitioners, allowing her to take her time and make sure that all your concerns are addressed and treated to your satisfaction. Dr. Wilson wants her clients to be able to get out and experience life, not just survive it.Website: https://luminouschirostl.comFacebook: https://www.facebook.com/drkristanwilsonInstagram: @dr.kristan.wilsonLinkedin: https://www.linkedin.com/in/kristan-wilson-dc-ms-ccac-52836b51/

Stacey Wilson of Therap Services, therap services aims to help people who work for those who have intellectual disabilities make their documentation to where they do their job by giving them the tool where they can have all the information they need. They provide documentation where you can have the information you need wherever you want to. They support those people who collect data and documentations in making those information safe, secure and accessible. To schedule a FREE real estate specialists consultation please contact Darryl Baskin and Pamela Wright of Baskin Real Estate Specialists powered by eXp Realty. DARRYL BASKIN Baskin Real Estate Specialists, eXp Realty Email: darryl@darrylbaskin.com Tel: 918 258 2600 Tel: 918 740 0077 Thinking of Selling? Get your FREE Home Valuation complete with local comparables instantly. https://www.homeguidetulsa.com/sell.php Looking to Purchase? Search thousands of current listings directly from our local MLS. https://www.homeguidetulsa.com/index.php?advanced=1&display=&custombox=&types[]=1&beds=0&baths=0&min=0&max=100000000&rtype=map#rslac

Stacey Wilson of Therap Services shares the things that she does as a direct support professional. She had provided support to people and worked for different organizations and that made her realize that it is what she wants to do. She wants to give people the support that they need to enhance what a person can do best to contribute to the community for everybody's effort is valuable in the community. That is what motivates her, to make those people that they are supporting be the star of the show. To schedule a FREE real estate specialists consultation please contact Darryl Baskin and Pamela Wright of Baskin Real Estate Specialists powered by eXp Realty. DARRYL BASKIN Baskin Real Estate Specialists, eXp Realty Email: darryl@darrylbaskin.com Tel: 918 258 2600 Tel: 918 740 0077 Thinking of Selling? Get your FREE Home Valuation complete with local comparables instantly. https://www.homeguidetulsa.com/sell.php Looking to Purchase? Search thousands of current listings directly from our local MLS. https://www.homeguidetulsa.com/index.php?advanced=1&display=&custombox=&types[]=1&beds=0&baths=0&min=0&max=100000000&rtype=map#rslac

GU Cast is back! Declan and Renu took a break over the Melbourne Summer and are fully recharged with a great schedule of podcasts coming up for 2021.We kick off today with the fourth in our series of webinar collaborations with the Prostate Cancer Foundation and the ProsTIC team at Peter MacCallum Cancer Centre. Today's webinar had 589 live attendees from more than 40 countries, tuning in to hear the latest in PSMA theranostics for advanced prostate cancer. ON GU Cast today we cross-post the audio from today's webinar focussing on the TheraP trial, recently published in the Lancet. TheraP is the first randomised trial of 177Lutetium PSMA theranostics, and is one of the most exciting areas of research in prostate cancer today. We are joined by both the first and senior authors, Professors Michael Hofman and Professor Ian Davis, as well as key members of the team who put this together, including funders, industry partners, and a panel of expert key opinion leaders including panellist Professor Louise Emmett. Special thanks to Dr Howard Soule and Dr Andrea Miyahira from the PCF, as well as Professor Michael Hofman and Annette Van Der Heyden from ProsTIC for putting this together. Links:The PCFProsTIC TheraP page at ANZUP Full webinar on YouTube

Music for Sleep, Meditation, Relaxation, Massage, Yoga, Reiki, Sound Healing and TherapyI'm hoping all of you and your loved ones and friends are being safe and healthy, and to continue so. We will all get through this togetherHi everyone my name is Jim Butler and welcome to Deep Energy Podcast 347 - Aura of the Heavens - REMASTERED. For my weekend retro podcasts I am going to start re-releasing my old collection of Dark Ambient Podcasts. I don't believe a lot of these are available anymore, you are in for a treat and how the podcast has evolved in the last 13 or so years. So this would be Dark Ambient # 17 and it was also released as Deep Energy # 53. It was originally released on June 27, 2008 and October 15, 2015. I remastered this, added a little depth to it and I think I brought out some more of the sounds that are hidden away in the earlier mixes. I also made the mix a little quieter too. This is another one where I put together 4 shorter pieces of music to make one podcast. I hope you enjoy it.If you would like to find out more about me and my music, head on over to www.JimButlerMusic.com or you can e-mail me at jimbutlermusic@gmail.com. On the website you will find links to all of my social media including FB, FB fan page, IG and Twitter and any live appearances I am making in the Keene, NH area. I now have a merchandise store with a collection of mugs, t-shirts, tote bags, hoody's and a ton more… you can find it at www.deepenergy.threadless.com This podcast is ad supported, if you would like to listen to the podcast without ads or speaking, please go to my Bandcamp page www.jimbutler.bandcamp.com and most of the podcasts are there. If you would like a podcast and you don't see it, just send me an e-mail and I will get it uploaded ASAP.Please share, subscribe, rate and review (helps more people find the podcast) through however you listen to the podcast including:Spreaker, Stitcher, Apple Podcast App, Pandora, Spotify, Luminary, iHeart Radio, Radio.com, Deezer, YouTube, Alexa and Siri and many other podcast providers.Thank you for listening. Until the next time, please be kind to one another, peace, bye….I am a sponsored runner from Rabbit clothing and you can get 10% off of your first Rabbit order using the link below. Thanks!!https://go.referralcandy.com/share/NZDZHD2

Music for Sleep, Meditation, Relaxation, Massage, Yoga, Reiki, Sound Healing and TherapyI’m hoping all of you and your loved ones and friends are being safe and healthy, and to continue so. We will all get through this togetherHi everyone my name is Jim Butler and welcome to Deep Energy Podcast 347 - Aura of the Heavens - REMASTERED. For my weekend retro podcasts I am going to start re-releasing my old collection of Dark Ambient Podcasts. I don’t believe a lot of these are available anymore, you are in for a treat and how the podcast has evolved in the last 13 or so years. So this would be Dark Ambient # 17 and it was also released as Deep Energy # 53. It was originally released on June 27, 2008 and October 15, 2015. I remastered this, added a little depth to it and I think I brought out some more of the sounds that are hidden away in the earlier mixes. I also made the mix a little quieter too. This is another one where I put together 4 shorter pieces of music to make one podcast. I hope you enjoy it.If you would like to find out more about me and my music, head on over to www.JimButlerMusic.com or you can e-mail me at jimbutlermusic@gmail.com. On the website you will find links to all of my social media including FB, FB fan page, IG and Twitter and any live appearances I am making in the Keene, NH area. I now have a merchandise store with a collection of mugs, t-shirts, tote bags, hoody’s and a ton more… you can find it at www.deepenergy.threadless.com This podcast is ad supported, if you would like to listen to the podcast without ads or speaking, please go to my Bandcamp page www.jimbutler.bandcamp.com and most of the podcasts are there. If you would like a podcast and you don’t see it, just send me an e-mail and I will get it uploaded ASAP.Please share, subscribe, rate and review (helps more people find the podcast) through however you listen to the podcast including:Spreaker, Stitcher, Apple Podcast App, Pandora, Spotify, Luminary, iHeart Radio, Radio.com, Deezer, YouTube, Alexa and Siri and many other podcast providers.Thank you for listening. Until the next time, please be kind to one another, peace, bye….I am a sponsored runner from Rabbit clothing and you can get 10% off of your first Rabbit order using the link below. Thanks!!https://go.referralcandy.com/share/NZDZHD2

After graduating from the Department of Computer Science and Engineering at the University of Dhaka, Safat joins Therap Services as a freshman software engineer. After four years in Therap, he joins Grab in April 2018 and then PayPal in January 2019. He is currently working as a Java backend engineer at PayPal's Singapore office. In this episode, we talked about Safat's journey as a software engineer. His university life. His life and academic and non-academic interests as a CSE student. Based on his current understanding of the software engineering field, what he thinks a CS student should focus on in early college days. We talked about his experience and observations as a software engineer both in Bangladesh and in the Singapore tech industry. We also talked about work from home and how big tech in Singapore is handling this global pandemic and many more. -- Profile of Today's Guest: https://www.linkedin.com/in/mshakhawat/ --- Send in a voice message: https://anchor.fm/banglatechtalk/message

Dr. Fábio Schutz, oncologista clínica da BP – A Beneficência Portuguesa de São Paulo, comenta os resultados do estudo fase II TheraP (ANZUP 1603), apresentado na sessão de tumores geniturinários da ASCO 2020. O estudo randomizou 200 pacientes com câncer de próstata metastático refratário a castração que haviam falhado a docetaxel para receberem cabazitaxel no braço controle versus 177Lu-PSMA-617 (LuPSMA) no braço experimental. O objetivo primário do estudo foi atingido, demonstrando superioridade de LuPSMA em relação a cabazitaxel, com taxa de resposta de PSA de 66% versus 37% respectivamente, uma diferença estatisticamente significante, com p < 0,0001. A sobrevida livre de progressão do PSA (PSA-PFS) também favoreceu o LuPSMA, assim como os eventos adversos de graus 3 ou 4, que foram relativamente menores no braço de LuPSMA. Confira o episódio e entenda os critérios de inclusão bem como os resultados da análise – que embora fase II – já demonstra a alta atividade dessa nova classe de terapia.

The Oncology Journal Club - Delivering Oncology News DifferentlyThe Oncology Podcast, brought to you by www.oncologynews.com.au, is proud to present the next episode of The Oncology Journal Club.This week we have our second post ASCO 2020 Review episode, hosted by the brilliant Professor Eva Segelov from Monash University. She is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Belgium.This week Eva interviews Professor Michael Hofman about the TheraP trial. Hans gets the ASCO Winners this week, Eva presents her Losers and Craig shares his favourite ‘Weird and Wonderful' papers from ASCO.The banter only get better so once again you are in for an entertaining and engaging episode of The Oncology Journal Club. As ever, the links to all the papers discussed today are available in the notes on our website.About The Oncology Journal ClubWe have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and studies presented at key meetings to help keep you informed of the latest developments on the go.For the latest oncology news visit www.oncologynews.com.au and for regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

Another most enjoyable webinar from our friends at the Prostate Cancer Foundation, this time focussing on the TheraP trial recently presented at #ASCO20, a randomised trial of Lu-PSMA vs cabazitaxel in progressive mCRPC. Professor Michael Hofman presents the data and is joined by an esteemed global panel including Professor Ian Davis, Professor Cora Sternberg and Professor Wolfgang Weber. Co-hosted by Professor Declan Murphy and Dr Howard Soule. More than 500 registrants from over 40 countries joined in, many of whom contributed to a very lively discussion. Enjoy!

Julie Benz (Dexter, Hawaii Five-0) joins us to talk about everything from issues with panic attacks and infertility to being surprisingly killed off of her dream role on the hit show Dexter after 4 years. Julie was absolutely amazing this week and opened up about how previous experiences with being left in the shadows and dealing with rejection fueled her fire to continue pursuing a successful career in acting. We also talk about what it’s like dating as we get older, Julie’s former life as a groomed child ice skater, and realizing that our work and roles don’t define who we are as people.Special thanks to Uncommon Apothecary CBD for sponsoring today’s show. Uncommon Apothecary CBD provides eco-friendly CBD products, all 3rd party tested to ensure quality and consistency. Head over to ua-cbd.com and use promo code “inside” to receive 20% off your purchase.

Welcome back to "Cave of Thrones!!!" Some pretty insane stuff is about to go down. Dating in Westeros seems pretty intense, we're just sayin'. In this episode, CraigMakk talk about how war....war never changes (from Vietnam to King's Landing); Serious Jest takes another opportunity to spring Aubrey on an unsuspecting Makk; and both guys dig deep into the insensitivity that GRRM and the show runners just might have toward women and minorities; how The Carlton might look in 2019; how much betrayal is too much for a Queen of Dragons to handle; when keeping it real goes wrong for Varys; and much, much more. Plus they bring Jim Sardonic on to be a moderator and move things along, and he does a surprisingly good job. All this while drinking some astonishingly great beers. So strap in, grab yourself a beer, and welcome back to "Cave of Therap...I mean Thrones!!!" Beer(s) of the Show: Bolero Snort 20th & Bull Imperial Stout, Dogfish Head American Beauty Pale Ale, and Rochester Mills Chocolate Cheesecake Milkshake Stout

After meeting with Gary Vaynerchuk, 3 time billion dollar brand builder Brian Lee, and going through a therapy workshop in LA Ryan Daniel Moran shares his insights and breakthroughs about business and life.

After meeting with Gary Vaynerchuk, 3 time billion dollar brand builder Brian Lee, and going through a therapy workshop in LA Ryan Daniel Moran shares his insights and breakthroughs about business and life... The post GaryVee, Brian Lee, and Therap-y” By Ryan Daniel Moran #TheOnePercent appeared first on Freedom Fast Lane.

This week, the girls take one of the most well-known personality tests: the Myers-Briggs Type Indicator! The test indicates if you are more extroverted or introverted, use intuition more than logic, and more. Kelsey and Delanie end up being the same personality type, and Taylor feels like she may have gotten incorrect results. If you do the test online, try to select "neutral" as few times as possible so you get a more accurate result! Subscribe to Self-Helpless on iTunes and give it a 5-star rating and review! 

Tami A. Goldstein is a certified massage therapist, with 10+ years of experience facilitating Upledger Craniosacral therapy to individuals with autism. A national advocate and educator for autism, she is the award winning author of “Coming Through the Fog.” When her infant daughter began displaying disturbing symptoms after vaccinations, Tami began educating herself. As her daughter’s conditions worsened, culminating in an autism diagnosis at age 13, she quit her job to pursue appropriate therapy full time, encountering a shocking range of reactions from unresponsive to overtly hostile.